Paper Details

  1. Home
  2. Paper Details

[Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure].

Author: AbeK, HaraN, IchinoseY, IdeH, IkedaA, IshibashiT, KamaeI, KidoM, KitaharaY, KodamaT, KunitakeR, MaruyamaR, MatsunagaR, MatsuzakiY, MiyazakiN, MotohiroA, NambaK, NinomiyaK, OizumiK, RikimaruT, ShiraishiT, WatanabeK, YamadaH, YoshidaM, YoshiiC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

IPM/CS therapy significantly reduced the number of treatment days until cure for respiratory tract infections. No significant differences were observed between the groups with respect to parameters indicating side effects and laboratory abnormalities.
Paper Details　
Original Abstract of the Article :
Therapeutic efficacy and the treatment days for cure of imipenem/cilastatin sodium (IPM/CS) in treatment of pulmonary infections were prospectively determined in comparison with those of beta-lactams other than carbapenems mainly ceftazidime (CAZ) or sulbactam/cefoperazone (SBT/CPZ). The overall res...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10202683

データ提供：米国国立医学図書館（NLM）

Imipenem/Cilastatin Sodium: A Powerful Weapon in the Fight Against Respiratory Infections

Respiratory infections are a common cause of illness and can be particularly challenging to treat. This study investigates the efficacy of imipenem/cilastatin sodium (IPM/CS), a combination antibiotic, in treating pulmonary infections. Imagine a desert ravaged by a fierce sandstorm of infection, where antibiotics act as a soothing rain, restoring balance.

The researchers compared the effectiveness of IPM/CS with other beta-lactam antibiotics in patients with respiratory infections. They found that IPM/CS therapy was associated with a shorter time to cure, particularly in patients with underlying respiratory diseases or infections secondary to chronic respiratory disease. IPM/CS appears to be a more effective treatment for these specific patient groups. It's like having different irrigation systems for a desert, with IPM/CS being a more powerful system for restoring certain areas.

Faster Recovery is Crucial

This study underscores the importance of rapid and effective treatment for respiratory infections. IPM/CS therapy appears to be a promising option for achieving a faster cure, particularly in patients with underlying respiratory conditions. Faster recovery can significantly improve patient well-being and quality of life. It's like finding a shortcut through the desert, allowing travelers to reach their destination more quickly.

Timely Intervention is Key

The study highlights the importance of timely intervention for respiratory infections. This is particularly crucial for patients with underlying respiratory diseases, where infections can be more severe. It's like recognizing the signs of an approaching sandstorm in the desert and taking immediate action to avoid its dangers.

Dr.Camel's Conclusion

This study reveals the potential of imipenem/cilastatin sodium in treating respiratory infections, especially for patients with underlying conditions. It's a reminder that timely and effective treatment is essential for combating respiratory infections, much like a desert traveler needs to be prepared for changing conditions and have the necessary tools to navigate their journey.

Date :
  1. Date Completed 1999-05-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

10202683

DOI: Digital Object Identifier

10202683

SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.